Treatment group | Drug name | ATC | OPS | Cancer type |
---|---|---|---|---|
Immunotherapy | Cetuximab’ | L01XC06 | 6–001.a | NSCLC |
Bevacizumab’ | L01XC07 | 6–002.9 | NSCLC | |
Ipilimumab | L01XC11 | 6–006.h | NSCLC | |
Nivolumab | L01XC17 | 6–008.m | NSCLC | |
Pembrolizumab | L01XC18 | 6–009.3 | NSCLC | |
Necitumumab’ | L01XC22 | 6–009.g | NSCLC | |
Durvalumab | L01XC28 | Â | NSCLC | |
Avelumab | L01XC31 | Â | NSCLC | |
Atezolizumab | L01XC32 | Â | NSCLC | |
Other immunotherapies |  | 8–547 |  | |
Inhibitors’ | Gefitinib | L01XE02 |  | NSCLC |
Erlotinib | L01XE03 | Â | NSCLC | |
Afatinib | L01XE13 | Â | NSCLC | |
Crizotinib | L01XE16 | 6–006.c | NSCLC | |
Dabrafenib | L01XE23 | 6–007.5 | NSCLC | |
Trametinib | L01XE25 | 6–009.7 | NSCLC | |
Ceritinib | L01XE28 | 6–008.a | NSCLC | |
Nintedanib | L01XE31 | Â | NSCLC | |
Osimertinib | L01XE35 | Â | NSCLC | |
Chemotherapy | Cyclophosphamide | L01AA01 | Â | SCLC |
Ifosfamide | L01AA06 | Â | SCLC | |
Trofosfamide | L01AA07 | Â | SCLC | |
Lomustine | L01AD02 | Â | SCLC | |
Temozolomide | L01AX03 | 6–002.e |  | |
Temozolomide | L01AX03 | 6–005.c |  | |
Pemetrexed | L01BA04 | 6–001.c | NSCLC | |
5-Fluoruracil | L01BC02 | Â | NSCLC | |
Gemcitabine | L01BC05 | 6–001.1 | NSCLC | |
Capecitabine | L01BC06 | Â | Â | |
Vinorelbine | L01CA04 | Â | NSCLC | |
Etoposide | L01CB01 | Â | SCLC | |
Nab-paclitaxel | L01CD01 | 6–005.d | NSCLC | |
Paclitaxel | L01CD01 | 6–001.f | NSCLC | |
Docetaxel | L01CD02 | 6–002.h |  | |
 | Doxorubicin | L01DB01 | 6–001.b | SCLC |
Doxorubicin | L01DB01 | 6–002.8 | SCLC | |
Epirubicin | L01DB03 | Â | SCLC | |
Mitomycin | L01DC03 | Â | NSCLC | |
Cisplatin | L01XA01 | Â | Â | |
Carboplatin | L01XA02 | Â | SCLC | |
Oxaliplatin | L01XA03 | Â | Â | |
Topotecan | L01XX17 | 6–002.4 | SCLC | |
Irinotecan | L01XX19 | 6–001.3 | SCLC | |
Liposomal irinotecan | L01XX19 | 6–009.e | SCLC | |
Folic acid | V03AF03 | Â | NSCLC | |
Non-complex chemotherapy |  | 8–542 |  | |
Moderately complex and intensive chemotherapy cycle |  | 8–543 |  | |
Highly complex and intensive chemotherapy cycle |  | 8–544 |  | |
Hyperthermic chemotherapy |  | 8–546 |  | |
Percutaneous closed organ perfusion with chemotherapeutic agents |  | 8–549 |  | |
Treatment group | Definition | EBM | OPS | Â |
Radiotherapy | Inpatient radiotherapy |  | OPS 8–52 |  |
High-voltage therapy | EBM 25320 EBM 25321 EBM 25322 EBM 25323 | Â | Â | |
Brachytherapy | EBM 25331 EBM 25333 | Â | Â | |
Radiotherapy planning | EBM 25340 EBM 25341 EBM 25342 | Â | Â | |
Studya | Â | EBM 13461 or EBM 13492 in conjunction with EBM 13494 | Â | Â |
 | EBM 02100 (at least 10 min) or EBM 02101 (at least 60 min) |  |  | |
 | EBM 01510 (2 h) EBM 01511 (4 h) EBM 01512 (6 h) |  |  | |
Other treatment | No documentation of previous treatment in the index quarter, in the first month of first-line therapy or second-line therapy, no documentation of previous treatment in the first quarter after the index quarter or the start of second-line therapy OR inpatient treatment (OPS 8–541) within one month after the index quarter or in the first month after the start of second-line therapy or treatments within one quarter after the index quarter or in the first quarter after the start of second-line therapy | |||
Not observable in line | See definition of other treatment in the first section AND no follow-up documentation of the patient during first-line or second-line therapy | |||
Late therapy | See definition of other treatment in the first section AND possible follow-up documentation of the patient during first-line or second-line therapy AND Documentation of previous treatments after first-line or second-line therapy | |||
No follow-up diagnosis | See definition of other treatment in the first section AND possible follow-up documentation of the patient during first-line or second-line therapy AND no repeated documentation of the diagnosis of lung cancer after the index quarter or in another quarter (violation of IC1) | |||
Surgical intervention, no therapy | See definition of other treatment in the first section AND possible follow-up documentation of the patient during first-line or second-line therapy AND repeated documentation of the diagnosis of lung cancer after the index quarter or in another quarter (satisfaction of IC1) AND documentation of an operation within the observation phase of first-line or second-line therapy (Table 2) | |||
Bronchoscopy, no surgical intervention, no therapy | See definition of other treatment in the first section AND possible follow-up documentation of the patient during first-line or second-line therapy AND repeated documentation of the diagnosis of lung cancer after the index quarter or in another quarter (satisfaction of IC1) AND no documentation of an operation within the observation phase of first-line or second-line therapy (Table 2) AND documentation of bronchoscopy within the observation phase of first-line or second-line therapy | |||
No bronchoscopy, no surgical intervention, no therapy | See definition of other treatment in the first section AND possible follow-up documentation of the patient during first-line or second-line therapy AND repeated documentation of the diagnosis of lung cancer after the index quarter or in another quarter (satisfaction of IC1) AND no documentation of an operation within the observation phase of first-line or second-line therapy (Table 2) AND No documentation of bronchoscopy within the observation phase of first-line or second-line therapy |